Indian drugmaker Cipla's Q1 profit misses estimates
23/07/2026 07:36
Indian drugmaker Cipla's Q1 profit misses estimates July 23 (Reuters) - Cipla CIPL.NS, one of India's largest drugmakers by revenue, reported a bigger-than-expected 39.2% fall in first-quarter profit, its third consecutive quarterly decline, as muted sales of generic cancer drugs and supply disruptions affecting lanreotide, a treatment for rare tumors, weighed on its U.S. business.
The company's consolidated net profit fell to 7.89 billion rupees ($81.73 million) in the quarter ended June 30. Analysts, on average, had expected profit at 8.17 billion rupees, according to data compiled by LSEG.
($1 = 96.5375 Indian rupees)
(Reporting by Rishika Sadam and Mridula Kumar in Bengaluru; Editing by Rashmi Aich)
Recent news on Dr. Reddy's Laboratories
See all newsDr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
Dr Reddy's beats quarterly profit estimate on India market lift (updated)
India's Dr Reddy's beats quarterly profit estimate
Brief: Dr. Reddy's Q2 Consol Net PAT 9.25 Billion Rupees
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption